A citation-based method for searching scientific literature

Chris J Scotton, Rachel C Chambers. Chest 2007
Times Cited: 404







List of co-cited articles
649 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
25

Idiopathic pulmonary fibrosis.
Talmadge E King, Annie Pardo, Moisés Selman. Lancet 2011
18

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
17

Pathogenesis of idiopathic pulmonary fibrosis.
Paul J Wolters, Harold R Collard, Kirk D Jones. Annu Rev Pathol 2014
360
16

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
14

Mechanisms of fibrosis: therapeutic translation for fibrotic disease.
Thomas A Wynn, Thirumalai R Ramalingam. Nat Med 2012
13

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
940
13

The myofibroblast: one function, multiple origins.
Boris Hinz, Sem H Phan, Victor J Thannickal, Andrea Galli, Marie-Luce Bochaton-Piallat, Giulio Gabbiani. Am J Pathol 2007
13

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
11

Incidence and prevalence of idiopathic pulmonary fibrosis.
Ganesh Raghu, Derek Weycker, John Edelsberg, Williamson Z Bradford, Gerry Oster. Am J Respir Crit Care Med 2006
791
10

Idiopathic pulmonary fibrosis.
Luca Richeldi, Harold R Collard, Mark G Jones. Lancet 2017
453
10

Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix.
Kevin K Kim, Matthias C Kugler, Paul J Wolters, Liliane Robillard, Michael G Galvez, Alexis N Brumwell, Dean Sheppard, Harold A Chapman. Proc Natl Acad Sci U S A 2006
891
10

Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.
Boris Hinz, Sem H Phan, Victor J Thannickal, Marco Prunotto, Alexis Desmoulière, John Varga, Olivier De Wever, Marc Mareel, Giulio Gabbiani. Am J Pathol 2012
777
9


Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.
Enrico Conte, Elisa Gili, Evelina Fagone, Mary Fruciano, Maria Iemmolo, Carlo Vancheri. Eur J Pharm Sci 2014
163
8

The impact of TGF-β on lung fibrosis: from targeting to biomarkers.
Isis E Fernandez, Oliver Eickelberg. Proc Am Thorac Soc 2012
338
8

Idiopathic pulmonary fibrosis.
T J Gross, G W Hunninghake. N Engl J Med 2001
721
7

Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition.
Jason R Rock, Christina E Barkauskas, Michael J Cronce, Yan Xue, Jeffrey R Harris, Jiurong Liang, Paul W Noble, Brigid L M Hogan. Proc Natl Acad Sci U S A 2011
577
7

Fibrotic extracellular matrix activates a profibrotic positive feedback loop.
Matthew W Parker, Daniel Rossi, Mark Peterson, Karen Smith, Kristina Sikström, Eric S White, John E Connett, Craig A Henke, Ola Larsson, Peter B Bitterman. J Clin Invest 2014
289
7

Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression.
Fei Liu, Justin D Mih, Barry S Shea, Alvin T Kho, Asma S Sharif, Andrew M Tager, Daniel J Tschumperlin. J Cell Biol 2010
429
7

A common MUC5B promoter polymorphism and pulmonary fibrosis.
Max A Seibold, Anastasia L Wise, Marcy C Speer, Mark P Steele, Kevin K Brown, James E Loyd, Tasha E Fingerlin, Weiming Zhang, Gunnar Gudmundsson, Steve D Groshong,[...]. N Engl J Med 2011
608
7

Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix.
Pierre-Jean Wipff, Daniel B Rifkin, Jean-Jacques Meister, Boris Hinz. J Cell Biol 2007
826
7

Fibroblasts in fibrosis: novel roles and mediators.
Ryan T Kendall, Carol A Feghali-Bostwick. Front Pharmacol 2014
384
7

NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury.
Louise Hecker, Ragini Vittal, Tamara Jones, Rajesh Jagirdar, Tracy R Luckhardt, Jeffrey C Horowitz, Subramaniam Pennathur, Fernando J Martinez, Victor J Thannickal. Nat Med 2009
567
7

Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
T Ashcroft, J M Simpson, V Timbrell. J Clin Pathol 1988
885
7


miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis.
Gang Liu, Arnaud Friggeri, Yanping Yang, Jadranka Milosevic, Qiang Ding, Victor J Thannickal, Naftali Kaminski, Edward Abraham. J Exp Med 2010
653
7

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
852
7

Pulmonary fibrosis: pathogenesis, etiology and regulation.
M S Wilson, T A Wynn. Mucosal Immunol 2009
420
6


The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?
Antje Moeller, Kjetil Ask, David Warburton, Jack Gauldie, Martin Kolb. Int J Biochem Cell Biol 2008
557
6

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.
Na Xie, Zheng Tan, Sami Banerjee, Huachun Cui, Jing Ge, Rui-Ming Liu, Karen Bernard, Victor J Thannickal, Gang Liu. Am J Respir Crit Care Med 2015
176
6



Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.
Tasha E Fingerlin, Elissa Murphy, Weiming Zhang, Anna L Peljto, Kevin K Brown, Mark P Steele, James E Loyd, Gregory P Cosgrove, David Lynch, Steve Groshong,[...]. Nat Genet 2013
414
6

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
854
6


Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis.
Chi Hung, Geoffrey Linn, Yu-Hua Chow, Akio Kobayashi, Kristen Mittelsteadt, William A Altemeier, Sina A Gharib, Lynn M Schnapp, Jeremy S Duffield. Am J Respir Crit Care Med 2013
198
6


Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis.
Brigham C Willis, Janice M Liebler, Katherine Luby-Phelps, Andrew G Nicholson, Edward D Crandall, Roland M du Bois, Zea Borok. Am J Pathol 2005
671
6

Molecular mechanisms of epithelial-mesenchymal transition.
Samy Lamouille, Jian Xu, Rik Derynck. Nat Rev Mol Cell Biol 2014
6

Idiopathic pulmonary fibrosis.
Eric B Meltzer, Paul W Noble. Orphanet J Rare Dis 2008
244
6

Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis.
Marco Chilosi, Venerino Poletti, Alberto Zamò, Maurizio Lestani, Licia Montagna, Paola Piccoli, Serena Pedron, Manuela Bertaso, Aldo Scarpa, Bruno Murer,[...]. Am J Pathol 2003
494
5

Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.
Luba Nalysnyk, Javier Cid-Ruzafa, Philip Rotella, Dirk Esser. Eur Respir Rev 2012
261
5

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
631
5

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
332
5



Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Lutz Wollin, Isabelle Maillet, Valérie Quesniaux, Alexander Holweg, Bernhard Ryffel. J Pharmacol Exp Ther 2014
295
5

Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44.
Yuejuan Li, Dianhua Jiang, Jiurong Liang, Eric B Meltzer, Alice Gray, Riu Miura, Lise Wogensen, Yu Yamaguchi, Paul W Noble. J Exp Med 2011
233
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.